The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The incidence of allergic conditions has continued to rise over the past several decades, with a growing body of research dedicated toward the treatment of such conditions. By driving a complex range of changes in the underlying immune response, immunotherapy is the only therapy that modulates the immune system with long-term effects and is presently utilized for the treatment of several atopic conditions. Recent efforts have focused on identifying biomarkers associated with these changes that may be of use in predicting patients with the highest likelihood of positive clinical outcomes during allergen immunotherapy (AIT), providing guidance regarding AIT discontinuation, and predicting symptomatic relapse and the need for booster AIT after therapy. The identification of such biomarkers in food allergy has the additional benefit of replacing oral food challenges, which are presently the gold standard for diagnosing food allergies. While several markers have shown early promise, research has yet to identify a marker that can invariably predict clinical response to AIT. Skin prick testing (SPT) and specific IgE have commonly been used as inclusion criteria for the initiation of AIT and prediction of reactions during subsequent allergen challenge; however, existing data suggests that changes in these markers are not always associated with clinical improvement and can be widely variable, reducing their utility in predicting clinical response. Similar findings have been described for the use of allergen-specific functional IgG4 antibodies, basophil activation and histamine release, and type 2 innate lymphoid cells. There appears to be a promising association between changes in the expression of dendritic cell-associated markers, as well as the use of DNA promoter region methylation patterns in the prediction of allergy status following therapy. The cellular and molecular changes brought about by immunotherapy are still under investigation, but major strides in our understanding are being made.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IgE and mast cells in allergic disease
Galli, S. J., & Tsai, M. (2012) · Nature Medicine · doi:10.1038/nm.2755 · Cited by 1,799
Kay, A. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440106 · Cited by 1,368
Allergen immunotherapy: A practice parameter third update
Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., Nelson, M., Weber, R., Bernstein, D. I., Blessing-Moore, J., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.034 · Cited by 1,256 · cited 1×
“For patients whose symptoms are not abated by conventional pharmacotherapies such as nasal glucocorticoids and antihistamines, allergen immunotherapy (AIT), in the form of subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT), is the only safe and effective option [1, 2] that reduces symptoms and the ne…”
Barrier Epithelial Cells and the Control of Type 2 Immunity
Hammad, H., & Lambrecht, B. N. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.007 · Cited by 847
Allergen injection immunotherapy for seasonal allergic rhinitis
Calderon, M. A., Alves, B., Jacobson, M., Hurwitz, B., Sheikh, A., & Durham, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001936.pub2 · Cited by 678
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
Bousquet, J., Schünemann, H. J., Samolinski, B., Demoly, P., Baena-Cagnani, C. E., Bachert, C., Bonini, S., Boulet, L. P., Bousquet, P. J., Brozek, J. L., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.053 · Cited by 623
Monitoring human basophil activation via CD63 monoclonal antibody 435
Knol, E. F., Mul, F. P. J., Jansen, H., Calafat, J., & Roos, D. (1991) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(91)90094-5 · Cited by 421
Casale, T. B., Busse, W. W., Kline, J. N., Ballas, Z. K., Moss, M. H., Townley, R. G., Mokhtarani, M., Seyfert-Margolis, V., Asare, A., Bateman, K., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.09.036 · Cited by 355 · cited 1×
“First studied as an adjunct in SCIT, omalizumab demonstrated significant reductions in adverse reactions [56, 57].”
Morita, H., Arae, K., Unno, H., Miyauchi, K., Toyama, S., Nambu, A., Oboki, K., Ohno, T., Motomura, K., Matsuda, A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.021 · Cited by 274
Wawrzyniak, P., Wawrzyniak, M., Wanke, K., Sokolowska, M., Bendelja, K., Rückert, B., Globinska, A., Jakiela, B., Kast, J. I., Idzko, M., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.050 · Cited by 241
Cited by
Brough, H. A., Nadeau, K. C., Sindher, S. B., Alkotob, S. S., Chan, S., Bahnson, H. T., Leung, D. Y. M., & Lack, G. (2020) · Allergy · doi:10.1111/all.14304 · Cited by 275
Self-citationA WAO—ARIA—GA2LEN Consensus Document on Molecular-Based Allergy Diagnosis (PAMD@): Update 2020
Ansotegui, I. J., Melioli, G., Canonica, G. W., Gómez, R. M., Jensen-Jarolim, E., Ebisawa, M., Luengo, O., Caraballo, L., Passalacqua, G., Poulsen, L. K., et al. (2020) · World Allergy Organization Journal · doi:10.1016/j.waojou.2019.100091 · Cited by 122
Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation
Sahiner, U. M., Giovannini, M., Escribese, M. M., Paoletti, G., Heffler, E., Alvaro Lozano, M., Barber, D., Canonica, G. W., & Pfaar, O. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050845 · Cited by 66
Metadata
- Authors
- Sindher, S. B., Long, A., Acharya, S., Sampath, V., & Nadeau, K. C.
- Venue
- Clinical Reviews in Allergy & Immunology
- Published
- 2018-02-17
- Volume
- 55
- Issue
- 2
- Pages
- 190-204
- ISSN
- 1080-0549 (ISSN-L)
- 1559-0267
- OpenAlex
- W2794440226
- Cited by
- 44
- References
- 18
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses. https://app.cochat.ai/papers/10.1007/s12016-018-8678-z
- The paper
- Sindher, S. B., Long, A., Acharya, S., Sampath, V., & Nadeau, K. C. (2018). The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses. Clinical Reviews in Allergy & Immunology. https://doi.org/10.1007/s12016-018-8678-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.